Oncolytic virotherapy for pancreatic cancer.
Oncolytic virotherapy for pancreatic cancer.
复制标题
DOI：
10.1017/s1462399411001876
复制
发表时间：
2011-05-18
影响因子：
6.2
通讯作者：
McFadden G
中科院分区：
文献类型：
--
作者：
Wennier S;Li S;McFadden G
在过去的十年中，许多溶瘤病毒（OV）已被研究作为胰腺癌的潜在治疗方法，其中一些目前正在进行临床试验。某些OV（如腺病毒、疱疹病毒和呼肠孤病毒）用于治疗胰腺癌的适用性已经被深入研究了几年，而其他最近研究的OV（如痘病毒和细小病毒）的适用性才刚刚开始确定。与此同时，研究已经确定了胰腺癌生物学的关键特征，这些特征提供了对这种疾病所涉及的重要因素或途径的更好理解。这篇综述的目的是总结不同的复制能力的OVs作为胰腺癌的治疗方法。它还专注于这些病毒的独特生物学，使它们成为胰腺癌令人兴奋的候选病毒疗法，并讨论了如何根据目前已知的胰腺癌分子生物学，对它们进行基因操作或与其他药物结合以提高其疗效。
Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.